Influence Factors Analysis Of Gefitinib For The Treatment Of Advanced Adenocarcinoma

Objective:Explore the influence factors of gefitinib for the treatment of advancedadenocarcinoma,which can guide tumor molecular targeted therapy of personalizedmedicine better.Methods:Collect clinical data of53no-smoking adenocarcinoma cases who haveparticipated the Expanded Access Program of Gefitinib in the2nd Affiliated Hospital ofDalian Medical University from June2008to December2011.All of them are receivingor have received oral Gefitinib monotherapy (250mg/d).The enrolled patients werefollowed up until death or December2011.The efficacy of Gefitinib，PFS and drugtoxicity were evaluated according to the international standards.The analysis of efficacyand survival were performed by SPSS13.0software.Results:1.The Response rate and disease control rate of gefitinib were41.5%and73.6%respectively. The median survival time and median progress free survival of all patientswere17and12months respectively.1-year survival rate were58.4%.2.Logisitic regression analysis showed that patients of Female,＜age70yearswere more sensitive to Gefitinib(P <0.05).3.Logisitic regression analysis showed that patients of Female,≥age70years andchemotherapy PFS≥six months were more stable in disease control(P <0.05).4.Cox proportion risk regression model shows that patients of KPS score≥80points, chemotherapy PFS≥six months had longer PFS(P <0.05).5.In female,no-smoking adenocarcinoma cases,younger patients of chemotherapy>2cycles has higher response rate(P <0.05).Elder group has longer PFS than youngergroup in any chemotherapy cycles(P <0.05). 6.Patients of chemotherapy>2cycles has better response rate and PFS than theones of chemotherapy≤2cycles in any age groups(P <0.05).7. I-Π level rash and diarrhea is the most common adverse reactions, but there wasno need special treatment.Conclusions:1.Young group patients have high efficiency in the treatment of gefitinib.Wespeculate that the possibility of genetic mutation is higher in this group.Chemotherapymay induce gene state changed,so that it influnces the efficiency of targeted therapy.2.Elder group patients have longer progression-free survival,it may have relatedwith tumor biological behaviour.3.NSCLC patients of more chemotherapy cycles and longer PFS getmore benefit for treatment of gefitinib.